Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective trial to evaluate the safety and efficacy of ATI-1501 in children with Clostridium difficile infection

Next Previous
X
Search
Trial Profile

A prospective trial to evaluate the safety and efficacy of ATI-1501 in children with Clostridium difficile infection

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Metronidazole (Primary)
  • Indications Clostridium difficile infections
  • Focus Adverse reactions
  • Sponsors Appili Therapeutics

    • Most Recent Events

    • 30 Oct 2017 According to an Appili Therapeutics media release, both the US Food and Drug Administration (FDA) and Health Canada have cleared its IND and CTA clinical investigation applications, respectively, to conduct a clinical trial of ATI-1501. The company will begin recruiting subjects in November 2017.
    • 28 Apr 2016 New trial record
    • 12 Apr 2016 According to an Appili Therapeutics media release, the company plans start clinical trials of ATI-1501 for Clostridium difficile infection in 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top